IGC Pharma IGC Income Statement (2010-2026)

NYSE IGC
$0.28 0.00 (-0.18%)
As of: Sep 10, 2026 · 2:42 PM EDT
Reported Financials

IGC Pharma Quarterly Income Statement

Periods 64 quarters
Latest Mar 2026

IGC Pharma income statement data for the quarter ended Mar 2026. This income statement covers 64 quarters of results from Jun 2010 through Mar 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue
0.08M0.06M0.14M0.12M0.21M0.20M0.33M0.17M0.56M0.29M0.20M0.29M0.27M0.41M0.26M0.33M0.66M0.19M
Cost of RevenueCost of Rev
0.05M0.02M0.08M0.05M0.07M0.07M0.23M0.10M0.30M0.12M0.07M0.12M0.11M0.21M0.15M0.18M0.35M0.09M
Gross Profit
0.03M0.04M0.06M0.07M0.14M0.14M0.10M0.06M0.26M0.17M0.13M0.17M0.16M0.20M0.10M0.15M0.31M0.10M
Operating items
Depreciation & Amortization - TotalDep. & Amort. (Tot)
Research & DevelopmentR&D
0.44M0.28M0.38M1.23M1.39M0.77M0.81M0.53M0.75M1.27M0.90M0.88M0.89M0.92M0.85M1.00M1.85M1.59M
Selling, General & AdministrativeSG&A
1.78M4.11M2.07M5.34M1.55M1.85M1.57M3.61M1.65M1.40M2.23M1.49M1.67M1.04M1.13M0.57M1.78M1.41M
Operating ExpensesOpex
2.22M4.39M2.45M6.57M2.94M2.62M2.38M4.14M2.39M2.67M3.13M2.37M2.56M1.96M1.98M1.57M3.63M3.00M
Operating IncomeOp. Inc
-2.19M-4.35M-2.38M-6.50M-2.80M-2.49M-2.28M-4.04M-2.14M-2.49M-3.00M-2.17M-2.40M-1.76M-1.88M-1.41M-3.32M-2.90M
EBIT
-2.19M-4.35M-2.38M-6.50M-2.80M-2.49M-2.28M-4.04M-2.14M-2.49M-3.00M-2.17M-2.40M-1.76M-1.88M-1.41M-3.32M-2.90M
Non-operating items
Non Operating Interest Expenses
Interest & Investment IncomeInt & Inv Inc
Other Non Operating IncomeOther Non Op Inc.
0.44M0.00M0.00M0.01M0.02M0.05M0.03M0.01M0.06M0.04M0.03M0.01M0.02M0.04M0.05M0.21M0.52M1.08M
Net income details
EBT
-1.79M-4.34M-2.38M-6.50M-2.79M-2.44M-2.25M-4.03M-2.08M-2.45M-5.59M-2.88M-2.38M-1.72M-1.83M-1.20M-2.80M-1.82M
Tax ProvisionsTaxes
-3.15M-2.42M-2.73M
Profit After TaxPAT
-1.87M-4.34M-2.38M-6.70M-3.00M-2.62M-2.31M-3.99M-2.08M-2.51M-5.59M-2.88M-2.38M-1.73M-1.85M-1.20M-2.80M-1.84M
Equity Income
Income from Non-Controlling InterestsInc. Minority
Income from Continuing OperationsIncome (Continuing)
-1.79M-4.34M-2.38M-3.35M-2.79M-2.44M-2.25M-1.61M-2.08M-2.45M-5.59M-0.15M-2.38M-1.72M-1.83M-1.20M-2.80M-1.82M
Consolidated Net IncomeConsol Net Inc.
-1.79M-4.34M-2.38M-3.35M-2.79M-2.44M-2.25M-1.61M-2.08M-2.45M-5.59M-0.15M-2.38M-1.72M-1.83M-1.20M-2.80M-1.82M
Income towards Parent CompanyParent Net Inc
-1.79M-4.34M-2.38M-3.35M-2.79M-2.44M-2.25M-1.61M-2.08M-2.45M-5.59M-0.15M-2.38M-1.72M-1.83M-1.20M-2.80M-1.82M
Net Income towards Common StockholdersNet Income
-1.79M-4.34M-2.38M-3.35M-2.79M-2.44M-2.25M-1.61M-2.08M-2.45M-5.59M-0.15M-2.38M-1.72M-1.83M-1.20M-2.80M-1.82M
Additional items
EPS (Basic)
-0.04-0.09-0.05-0.07-0.05-0.05-0.04-0.03-0.04-0.05-0.090.00-0.03-0.02-0.02-0.02-0.03-0.02
EPS (Diluted)
-0.06-0.15-0.08-0.12-0.10-0.09-0.08-0.06-0.07-0.05-0.090.00-0.03-0.02-0.02-0.02-0.03-0.02
Shares Outstanding
47.91M49.95M51.05M49.99M51.62M52.19M53.06M52.58M53.08M54.30M63.73M58.84M72.81M76.01M77.63M79.66M83.03M90.46M90.46M98.16M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
28.17M28.17M28.17M28.17M28.17M28.17M28.17M28.17M28.17M54.30M63.73M58.84M72.81M76.01M77.63M79.66M83.03M90.46M90.46M98.16M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
48.28M51.04M51.05M51.05M51.84M53.06M53.08M53.08M53.08M63.71M63.73M66.69M75.64M76.64M78.20M80.88M84.14M91.96M98.80M
EBITDA
-2.19M-4.35M-2.38M-6.50M-2.80M-2.49M-2.28M-4.04M-2.14M-2.49M-3.00M-2.17M-2.40M-1.76M-1.88M-1.41M-3.32M-2.90M
Interest ExpensesInt Expense
Tax Rate
48.49%59.95%94.63%